I IRONWOOD PHARMACEUTICALS INC
| Market Cap | $578.04M |
| P/E Ratio | 23.63 |
| Forward P/E | 2.43 |
| Dividend Yield | — |
| Beta | 0.19 |
| 52W Range | $0.53 - $5.78 |
| # Hedge Funds | 0 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
Hedge Fund Ownership
| Investor 0 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|
Insider Trading
| Insider Name of the company insider who made the trade 30 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| DENNER ALEXANDER J | Sale | 5,800 | $3.31 | $19.20K | 17 Mar 2026 | 13 Mar 2026 |
| DENNER ALEXANDER J | Sale | 6,725,000 | $3.05 | $20.51M | 17 Mar 2026 | 13 Mar 2026 |
| Ronald SilverPrincipal Accounting Officer | Sale | 12,621 | $3.66 | $46.19K | 24 Feb 2026 | 25 Feb 2026 |
| Michael ShetzlineSVP, CMO, Head-Res&Drug | Sale | 17,012 | $3.66 | $62.26K | 24 Feb 2026 | 25 Feb 2026 |
| Thomas A MccourtChief Executive Officer | Sale | 103,526 | $3.66 | $378.91K | 24 Feb 2026 | 25 Feb 2026 |
| Minardo JohnChief Legal Officer | Sale | 19,053 | $3.66 | $69.73K | 24 Feb 2026 | 25 Feb 2026 |
| Gregory S. MartiniChief Financial Officer | Sale | 11,457 | $3.66 | $41.93K | 24 Feb 2026 | 25 Feb 2026 |
| Tammi L GaskinsChief Commercial Officer | Sale | 11,239 | $3.66 | $41.13K | 24 Feb 2026 | 25 Feb 2026 |
| Silver RonaldPrincipal Accounting Officer | Sale | 12,621 | $3.66 | $46.19K | 24 Feb 2026 | 25 Feb 2026 |
| MCCOURT Thomas AChief Executive Officer | Sale | 103,526 | $3.66 | $378.91K | 24 Feb 2026 | 25 Feb 2026 |
| Gaskins Tammi LChief Commercial Officer | Sale | 11,239 | $3.66 | $41.13K | 24 Feb 2026 | 25 Feb 2026 |
| John MinardoChief Legal Officer | Sale | 19,053 | $3.66 | $69.73K | 24 Feb 2026 | 25 Feb 2026 |
| Shetzline MichaelSVP, CMO, Head-Res&Drug | Sale | 17,012 | $3.66 | $62.26K | 24 Feb 2026 | 25 Feb 2026 |
| Martini Gregory S.Chief Financial Officer | Sale | 11,457 | $3.66 | $41.93K | 24 Feb 2026 | 25 Feb 2026 |
| Michael ShetzlineSVP, CMO, Head-Res&Drug | Sale | 15,570 | $3.81 | $59.32K | 23 Feb 2026 | 25 Feb 2026 |
| Gregory S. MartiniChief Financial Officer | Sale | 10,487 | $3.81 | $39.96K | 23 Feb 2026 | 25 Feb 2026 |
| Thomas A MccourtChief Executive Officer | Sale | 94,757 | $3.81 | $361.02K | 23 Feb 2026 | 25 Feb 2026 |
| Minardo JohnChief Legal Officer | Sale | 17,439 | $3.81 | $66.44K | 23 Feb 2026 | 25 Feb 2026 |
| Tammi L GaskinsChief Commercial Officer | Sale | 10,287 | $3.81 | $39.19K | 23 Feb 2026 | 25 Feb 2026 |
| Ronald SilverPrincipal Accounting Officer | Sale | 11,552 | $3.81 | $44.01K | 23 Feb 2026 | 25 Feb 2026 |
| Silver RonaldPrincipal Accounting Officer | Sale | 11,552 | $3.81 | $44.01K | 23 Feb 2026 | 25 Feb 2026 |
| MCCOURT Thomas AChief Executive Officer | Sale | 94,757 | $3.81 | $361.02K | 23 Feb 2026 | 25 Feb 2026 |
| Gaskins Tammi LChief Commercial Officer | Sale | 10,287 | $3.81 | $39.19K | 23 Feb 2026 | 25 Feb 2026 |
| John MinardoChief Legal Officer | Sale | 17,439 | $3.81 | $66.44K | 23 Feb 2026 | 25 Feb 2026 |
| Shetzline MichaelSVP, CMO, Head-Res&Drug | Sale | 15,570 | $3.81 | $59.32K | 23 Feb 2026 | 25 Feb 2026 |
| Martini Gregory S.Chief Financial Officer | Sale | 10,487 | $3.81 | $39.96K | 23 Feb 2026 | 25 Feb 2026 |
| Silver RonaldPrincipal Accounting Officer | Sale | 35,416 | $4.60 | $162.91K | 05 Jan 2026 | 07 Jan 2026 |
| Ronald SilverPrincipal Accounting Officer | Sale | 35,416 | $4.60 | $162.91K | 05 Jan 2026 | 07 Jan 2026 |
| Gaskins Tammi LChief Commercial Officer | Sale | 6,016 | $3.32 | $19.97K | 17 Nov 2025 | 19 Nov 2025 |
| Tammi L GaskinsChief Commercial Officer | Sale | 6,016 | $3.32 | $19.97K | 17 Nov 2025 | 19 Nov 2025 |
Frequently Asked Questions
What is IRWD stock price today?
IRONWOOD PHARMACEUTICALS INC (IRWD) is currently trading at $3.55. The stock has a 52-week range of $0.53 to $5.78 and a market capitalization of $578.04M.
Is IRWD a good stock to buy in 2026?
IRONWOOD PHARMACEUTICALS INC has a P/E ratio of 23.6 (forward P/E: 2.4), a dividend yield of none, and 1-year performance of +149.0%. 0 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling IRWD stock?
There have been 30 insider transactions for IRWD in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has IRWD stock performed over the past year?
IRONWOOD PHARMACEUTICALS INC (IRWD) has returned +149.0% over the past 12 months. The stock traded between $0.53 and $5.78 during this period, and is currently at $3.55.
Which hedge funds own IRWD (IRONWOOD PHARMACEUTICALS INC)?
0 tracked hedge funds currently hold IRWD in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is IRWD's market cap and valuation?
IRONWOOD PHARMACEUTICALS INC (IRWD) has a market capitalization of $578.04M. The trailing P/E ratio is 23.6 and forward P/E is 2.4. The stock is classified in the Healthcare sector.
What is IRWD's revenue and profitability?
IRONWOOD PHARMACEUTICALS INC reported revenue of $296.15M with net income of $24.02M and a profit margin of 0.08%. The stock has a beta of 0.19.
What sector is IRWD in and who are its biggest institutional holders?
IRONWOOD PHARMACEUTICALS INC (IRWD) operates in the Healthcare sector. It is held by 0 tracked hedge funds. See the ownership table above for the complete list.